How would you approach treating patients with RA refractory to cDMARDs and a prior history of MALT lymphoma?
Answer from: at Academic Institution
If the concern is the risk of recurrence of lymphoma in a patient with RA requiring DMARD therapy, particularly biologic DMARD therapy, rituximab has not been associated with recurrence or even new onset lymphoma. Rituximab is a highly efficacious biologic DMARD for seropositive RA. This is consiste...
Sign in or Register to read more